» Articles » PMID: 11959894

Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies

Overview
Specialty Oncology
Date 2002 Apr 18
PMID 11959894
Citations 641
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Reproductive and hormonal factors are involved in the etiology of breast cancer, but there are only a few prospective studies on endogenous sex hormone levels and breast cancer risk. We reanalyzed the worldwide data from prospective studies to examine the relationship between the levels of endogenous sex hormones and breast cancer risk in postmenopausal women.

Methods: We analyzed the individual data from nine prospective studies on 663 women who developed breast cancer and 1765 women who did not. None of the women was taking exogenous sex hormones when their blood was collected to determine hormone levels. The relative risks (RRs) for breast cancer associated with increasing hormone concentrations were estimated by conditional logistic regression on case-control sets matched within each study. Linear trends and heterogeneity of RRs were assessed by two-sided tests or chi-square tests, as appropriate.

Results: The risk for breast cancer increased statistically significantly with increasing concentrations of all sex hormones examined: total estradiol, free estradiol, non-sex hormone-binding globulin (SHBG)-bound estradiol (which comprises free and albumin-bound estradiol), estrone, estrone sulfate, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone. The RRs for women with increasing quintiles of estradiol concentrations, relative to the lowest quintile, were 1.42 (95% confidence interval [CI] = 1.04 to 1.95), 1.21 (95% CI = 0.89 to 1.66), 1.80 (95% CI = 1.33 to 2.43), and 2.00 (95% CI = 1.47 to 2.71; P(trend)<.001); the RRs for women with increasing quintiles of free estradiol were 1.38 (95% CI = 0.94 to 2.03), 1.84 (95% CI = 1.24 to 2.74), 2.24 (95% CI = 1.53 to 3.27), and 2.58 (95% CI = 1.76 to 3.78; P(trend)<.001). The magnitudes of risk associated with the other estrogens and with the androgens were similar. SHBG was associated with a decrease in breast cancer risk (P(trend) =.041). The increases in risk associated with increased levels of all sex hormones remained after subjects who were diagnosed with breast cancer within 2 years of blood collection were excluded from the analysis.

Conclusion: Levels of endogenous sex hormones are strongly associated with breast cancer risk in postmenopausal women.

Citing Articles

Multilayer analysis of ethnically diverse blood and urine biomarkers for breast cancer risk and prognosis.

Feng J, Qi X, Chen C, Li B, Wang M, Xie X Sci Rep. 2025; 15(1):6791.

PMID: 40000747 PMC: 11861975. DOI: 10.1038/s41598-025-90447-9.


Biological embodiment of educational attainment and future risk of breast cancer: findings from a French prospective cohort.

Berger E, Dudouet R, Dossus L, Baglietto L, Gelot A, Boutron-Ruault M BMJ Open. 2025; 15(2):e087537.

PMID: 39915021 PMC: 11800216. DOI: 10.1136/bmjopen-2024-087537.


Mediation effects of metabolites and sex hormones on the relationship between body mass index and breast cancer: Mendelian randomization analysis and mediation analysis.

Yang Y, Chen M, Yang W Front Oncol. 2024; 14:1449956.

PMID: 39640279 PMC: 11617525. DOI: 10.3389/fonc.2024.1449956.


The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER + breast cancer but not ER- breast cancer.

Bi K, Chen M, Zhao Q, Yang T, Xie W, Ma W Breast Cancer Res. 2024; 26(1):161.

PMID: 39587695 PMC: 11587662. DOI: 10.1186/s13058-024-01923-5.


The role of gut microbial β-glucuronidases in carcinogenesis and cancer treatment: a scoping review.

Hillege L, Stevens M, Kristen P, de Vos-Geelen J, Penders J, Redinbo M J Cancer Res Clin Oncol. 2024; 150(11):495.

PMID: 39537966 PMC: 11561038. DOI: 10.1007/s00432-024-06028-2.